TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24795142

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole prophylaxis
Number of subjects: 607

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study: 23276563

Group type: EXPERIMENTAL
Intervention: Hydrodistention plus bladder training (HD plus BT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Hydrodistention (HD)
Number of subjects: 70
Study: 20133499

Group type: EXPERIMENTAL
Intervention: Anti-EGFR therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigational predictive molecular markers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing clinical trials
Number of subjects: 0
Study: 18332845

Group type: EXPERIMENTAL
Intervention: Haloperidol 0.5 mg TID, administered from up to 72 hours preoperatively until the third postoperative day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15973347

Group type: EXPERIMENTAL
Intervention: Iron supplementation for 30 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12641541

Group type: EXPERIMENTAL
Intervention: Insulin lispro (0.2 Iu kg‐1) and vitamin C (1-g daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11043699

Group type: EXPERIMENTAL
Intervention: CATCH children (intervention group)
Number of subjects: 5106
Study: 8653152

Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 1947866

Group type: EXPERIMENTAL
Intervention: Day treatment with community care
Number of subjects: 50
Study: 6664681

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (mock transcutaneous nerve stimulation)
Number of subjects: 62
Study: 31930895

Group type: EXPERIMENTAL
Intervention: Plum-blossom needle tapping at three yin meridians of wrist combined with rehabilitation training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Simple rehabilitation training
Number of subjects: 72
Study: 30334877

Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 398
Study: 27333261

Group type: EXPERIMENTAL
Intervention: ABC+ (additional smoking cessation advice for 3 months)
Number of subjects: 39

Group type: COMPARATOR
Intervention: ABC (brief advice and subsidized nicotine replacement therapy)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both ABC and ABC+
Number of subjects: 39
Study: 27296663

Group type: EXPERIMENTAL
Intervention: Parent intervention (PI)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Student intervention (SI)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Combined intervention (CI)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 3000
Study: 25148255

Group type: EXPERIMENTAL
Intervention: Warfarin induction therapy
Number of subjects: 99
Study: 22432932

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1210
Study: 19914560

Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery with adjuvant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimodality therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variations in staging methods, surgical technique, radiotherapy technique, and chemotherapy regime
Number of subjects: 0
Study: 17324220

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 240 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15644624

Group type: EXPERIMENTAL
Intervention: 600 mg moclobemide daily for 6 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 11872193

Group type: EXPERIMENTAL
Intervention: Computer-generated decisions
Number of subjects: 53

Group type: COMPARATOR
Intervention: Clinicians' decisions
Number of subjects: 53
Study: 9571274

Group type: EXPERIMENTAL
Intervention: Collagen shields soaked in trifluridine (TFT) for at least 30 minutes preoperatively.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group received drops of TFT only.
Number of subjects: 11
Study: 7890499

Group type: EXPERIMENTAL
Intervention: Normal eyes (without ROP residua)
Number of subjects: 1694

Group type: COMPARATOR
Intervention: Eyes with retinal residua of ROP
Number of subjects: 1694

Group type: EXPERIMENTAL
Intervention: Overall acuity comparison
Number of subjects: 1694
Study: 3448228

Group type: EXPERIMENTAL
Intervention: DRAMS scheme (n = 34)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Simple advice only (n = 32)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Non-intervention control group (n = 38)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Sample as a whole
Number of subjects: 104
Study: 29144805

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily (SITA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lifestyle intervention alone (CON)
Number of subjects: 30
Study: 27511501

Group type: EXPERIMENTAL
Intervention: Enteral with enteral immunonutrition (ENIN)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Enteral only (EN)
Number of subjects: 41
Study: 25022781

Group type: EXPERIMENTAL
Intervention: Extinction trials (experimental condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counterconditioning trials (experimental condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filler task (control condition)
Number of subjects: 0
Study: 22869627

Group type: EXPERIMENTAL
Intervention: Sleeper stretch program (n = 30)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (n = 32)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dominant side
Number of subjects: 62
Study: 21029621

Group type: EXPERIMENTAL
Intervention: Early intervention (coronary angiography ≤ 24 h after randomization)
Number of subjects: 815

Group type: COMPARATOR
Intervention: Delayed intervention (coronary angiography ≥ 36 h after randomization)
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 815

Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 815
Study: 18432391

Group type: EXPERIMENTAL
Intervention: Self-administered TLFB
Number of subjects: 70

Group type: COMPARATOR
Intervention: Telephone-administered TLFB
Number of subjects: 70
Study: 18777143

Group type: EXPERIMENTAL
Intervention: Novel mental health service intervention
Number of subjects: 320
Study: 14962967

Group type: EXPERIMENTAL
Intervention: Arthrographic distension with saline and steroid
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (arthrogram)
Number of subjects: 48
Study: 12664761

Group type: EXPERIMENTAL
Intervention: Musculo‐skeletal medicine physician
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Conventional orthopaedic surgeon‐led service
Number of subjects: 1326
Study: 9409315

Group type: EXPERIMENTAL
Intervention: Fradafiban (dose producing > 80% fibrinogen receptor occupancy)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Aspirin 330 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fradafiban
Number of subjects: 18
Study: 8518408

Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 240 mg/day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 40 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Second line TOR or TAM treatment
Number of subjects: 66
Study: 3316874

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 10
Study: 11560537

Group type: EXPERIMENTAL
Intervention: QI-meds (n = 424 patients)
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: QI-therapy (n = 489 patients)
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Usual care (n = 443 patients)
Number of subjects: 1356
Study: 30818320

Group type: EXPERIMENTAL
Intervention: Implant systems with the same surface and different design
Number of subjects: 21
Study: 30563479

Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (12 months of primarily aerobic based exercise training)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control (standard nephrological care)
Number of subjects: 142

Group type: COMPARATOR
Intervention: CKD‐EPIcys
Number of subjects: 142

Group type: COMPARATOR
Intervention: CKD‐EPIcr‐cys
Number of subjects: 142

Group type: COMPARATOR
Intervention: MDRDcr
Number of subjects: 142
Study: 26466947

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg add-on therapy to interferon β1b
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo add-on therapy to interferon β1b
Number of subjects: 154
Study: 24784827

Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT)
Number of subjects: 2861

Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 2861
Study: 22917991

Group type: EXPERIMENTAL
Intervention: Silorane-based resin composite (Filtek P90/Adhesive System‐3M ESPE)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional methacrylate-based resin composite (Filtek P60/ Adper SE Plus‐3M ESPE)
Number of subjects: 33
Study: 20218866

Group type: EXPERIMENTAL
Intervention: Buffy Coat-Platelet Rich Plasma (BC-PRP)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (non-PRP treated sites)
Number of subjects: 2
Study: 17509693

Group type: EXPERIMENTAL
Intervention: 10-session, protocol continuation-phase therapy for 8 months
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control cohort (stopped protocol treatment after the acute-phase)
Number of subjects: 79
Study: 15129317

Group type: COMPARATOR
Intervention: Cyclosporin alone (3.5 mg/kg/day) for three months
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cyclosporin (3.5 mg/kg/day) plus topical calcipotriol cream twice a day for three months
Number of subjects: 54
Study: 12472705

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg x kg(‐1) with ketamine 1.8 mg x kg(‐1) (MK‐1)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg x kg(‐1) with ketamine 3 mg x kg(‐1) (MK‐2)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Midazolam 0.5 mg x kg(‐1) (MD)
Number of subjects: 79
Study: 9659858

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olanzapine 30-40 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olanzapine 10-20 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olanzapine 30 mg/day and higher
Number of subjects: 15
Study: 8134224

Group type: EXPERIMENTAL
Intervention: DTaP
Number of subjects: 165

Group type: COMPARATOR
Intervention: DTwP
Number of subjects: 165
Study: 2594924

Group type: EXPERIMENTAL
Intervention: 0.2 mg clonidine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 30 mg yohimbine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 6
Study: 29110996

Group type: EXPERIMENTAL
Intervention: PAC burden (number per hour) assessed by 24‐hour ambulatory ECG monitoring
Number of subjects: 938

Group type: COMPARATOR
Intervention: Baseline PAC burden
Number of subjects: 938

Group type: COMPARATOR
Intervention: PVC burden
Number of subjects: 938
Study: 26110890

Group type: EXPERIMENTAL
Intervention: 1‐month weight loss (WL) of 2‐4%
Number of subjects: 2290

Group type: EXPERIMENTAL
Intervention: 1‐month weight loss (WL) of >4%
Number of subjects: 2290

Group type: EXPERIMENTAL
Intervention: 2‐month weight loss (WL) of 3‐6%
Number of subjects: 2290

Group type: EXPERIMENTAL
Intervention: 2‐month weight loss (WL) of >6%
Number of subjects: 2290
Study: 23307281

Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 100

Group type: COMPARATOR
Intervention: MenC-CRM197
Number of subjects: 100
Study: 21775918

Group type: EXPERIMENTAL
Intervention: Infusion with 20 mg of nafamostat mesilate (group B)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Infusion with 50 mg of nafamostat mesilate (group C)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (20 mg) in low-risk patients
Number of subjects: 595

Group type: COMPARATOR
Intervention: Control in low-risk patients
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (50 mg) in low-risk patients
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (20 mg) in high-risk patients
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (50 mg) in high-risk patients
Number of subjects: 595

Group type: COMPARATOR
Intervention: Control in high-risk patients
Number of subjects: 595
Study: 18620801

Group type: EXPERIMENTAL
Intervention: Topiramate alone
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Amitriptyline alone
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combination of topiramate and amitriptyline
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study: 16407642

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (500 mg slow-release vitamin C and 272 IU vitamin E for 4 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment (100% O2, 2.4 bar, 131 min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normoatmospheric protocol (21% O2, 1.0 bar, 131 min)
Number of subjects: 19
Study: 14645636

Group type: EXPERIMENTAL
Intervention: Radiotherapy with concurrent administration of cisplatin
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Induction cisplatin plus fluorouracil followed by radiotherapy
Number of subjects: 547

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Radiotherapy with concurrent cisplatin
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy and cisplatin
Number of subjects: 547
Study: 10589807

Group type: EXPERIMENTAL
Intervention: Test Sc/RP (scaling and root planing performed from approximately 1 mm coronal to the probeable pocket)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control Sc/RP (scaling and root planing performed at the bottom of the probeable pocket)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control Sc/RP
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Test Sc/RP
Number of subjects: 7
Study: 9167419

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 64
Study: 2020050

Group type: EXPERIMENTAL
Intervention: Vaginal sonography
Number of subjects: 175

Group type: COMPARATOR
Intervention: Abdominal sonography
Number of subjects: 175
Study: 7060821

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 40 mg penbutolol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Combination therapy (propranolol or metoprolol with chlorthalidone)
Number of subjects: 21
Study: 30830964

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Morphine-3-glucuronide (M3G)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (M6G)
Number of subjects: 30
Study: 27989501

Group type: EXPERIMENTAL
Intervention: DFA-02 gel (gentamicin 16.8 mg/mL and vancomycin 18.8 mg/mL)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 445

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: DFA-02 gel
Number of subjects: 445

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 445
Study: 27057883

Group type: EXPERIMENTAL
Intervention: Hole ICL
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional ICL
Number of subjects: 32
Study: 25084280

Group type: EXPERIMENTAL
Intervention: AP (Armolipid Plus)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 22744524

Group type: EXPERIMENTAL
Intervention: Smart brace
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard rigid brace
Number of subjects: 12
Study: 19574761

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study: 17887946

Group type: EXPERIMENTAL
Intervention: Fast food Mediterranean-type diet for 4 weeks (groups A and B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular diet (group C)
Number of subjects: 45
Study: 15151774

Group type: EXPERIMENTAL
Intervention: Stent implantation with balloon predilatation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Direct stenting without balloon predilatation
Number of subjects: 100
Study: 11153970

Group type: EXPERIMENTAL
Intervention: Graded exposure in vivo treatment
Number of subjects: 4

Group type: COMPARATOR
Intervention: Graded activity
Number of subjects: 4
Study: 9471067

Group type: EXPERIMENTAL
Intervention: Savage technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tajima technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halsted technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Silfverskiold technique
Number of subjects: 40
Study: 8197551

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (7 Gy in one fraction)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (17.5 Gy in five fractions of 3.5 Gy each)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Preoperative group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Postoperative group
Number of subjects: 84
Study: 3371389

Group type: EXPERIMENTAL
Intervention: metoprolol CR (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: metoprolol SR (100 mg)
Number of subjects: 12
Study: 31119512

Group type: EXPERIMENTAL
Intervention: Group-based social skills interventions (GSSIs) for individuals with autism spectrum disorder (ASD)
Number of subjects: 17
Study: 27651514

Group type: EXPERIMENTAL
Intervention: HYD intact 60 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HYD chewed 60 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HYD milled to fine particles 60 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrocodone solution 60 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pupillometry measurements with HYD intact and HYD chewed
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrocodone solution, HYD fine particles, HYD chewed, and HYD intact
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Safety measures
Number of subjects: 40
Study: 25782852

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo acupuncture (sham acupuncture)
Number of subjects: 76
Study: 23668896

Group type: EXPERIMENTAL
Intervention: Skill-building intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 0
Study: 21427643

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT), up to 10 sessions for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Enhanced usual care (regular, brief telephone calls, and referrals to primary care provider as needed)
Number of subjects: 76
Study: 18791817

Group type: EXPERIMENTAL
Intervention: Children with GI problems (22.7% of the sample)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Children without GI problems
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Children with GI problems
Number of subjects: 172
Study: 17045826

Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg bd)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cilomilast (15 mg bd)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15266207

Group type: EXPERIMENTAL
Intervention: Risk assessment program with genetic counseling about lifetime risk based on gender, family history, and APOE genotype.
Number of subjects: 375
Study: 11511128

Group type: EXPERIMENTAL
Intervention: Jobs portrayed with male workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Jobs portrayed with female workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel jobs
Number of subjects: 0
Study: 9304515

Group type: EXPERIMENTAL
Intervention: Multimodality therapy (chemotherapy and irradiation)
Number of subjects: 0
Study: 8492199

Group type: EXPERIMENTAL
Intervention: 40 mg of methylprednisolone given intravenously before operation in combination with orally administered rapid‐release and sustained‐release diclofenac preparations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac alone
Number of subjects: 0
Study: 2963645

Group type: EXPERIMENTAL
Intervention: Eleutherococcus senticosus extract (10 ml, ethanolic preparation, 3 times daily for 4 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (additional wine with identical ethanol concentration)
Number of subjects: 36
Study: 2702236

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline
Number of subjects: 0
Study: 31561336

Group type: EXPERIMENTAL
Intervention: Knee-length compression stockings with an interface pressure of 18-21 mmHg (stocking type 1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Knee-length compression stockings with an interface pressure of 23-32 mmHg (stocking type 2)
Number of subjects: 19
Study: 28899418

Group type: EXPERIMENTAL
Intervention: Web course plus CPR training
Number of subjects: 432

Group type: COMPARATOR
Intervention: CPR training only (control)
Number of subjects: 432
Study: 25463964

Group type: EXPERIMENTAL
Intervention: Implementation intentions using a volitional help sheet
Number of subjects: 243

Group type: COMPARATOR
Intervention: General information about the risks of speeding (Control)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 243
Study: 23918578

Group type: EXPERIMENTAL
Intervention: Meloxicam + Pregabalin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 89

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 89
Study: 22015120

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC)
Number of subjects: 183
Study: 18929499

Group type: EXPERIMENTAL
Intervention: GH 1mg/m(2)/day
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control group (short young SGA adults)
Number of subjects: 292
Study: 17127777

Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide and salbutamol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Salbutamol alone
Number of subjects: 60